Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5180282
Max Phase: Preclinical
Molecular Formula: C32H37N7O4
Molecular Weight: 583.69
Associated Items:
ID: ALA5180282
Max Phase: Preclinical
Molecular Formula: C32H37N7O4
Molecular Weight: 583.69
Associated Items:
Canonical SMILES: COc1cc(C(=O)N2[C@H]3CC[C@@H]2[C@H](N)C3)cc2nc(-c3cc4ccc([C@@H](C)N5CCOC5=O)nc4n3CC3CC3)c(C)n12
Standard InChI: InChI=1S/C32H37N7O4/c1-17(36-10-11-43-32(36)41)24-8-6-20-12-26(37(30(20)34-24)16-19-4-5-19)29-18(2)38-27(35-29)13-21(14-28(38)42-3)31(40)39-22-7-9-25(39)23(33)15-22/h6,8,12-14,17,19,22-23,25H,4-5,7,9-11,15-16,33H2,1-3H3/t17-,22+,23-,25-/m1/s1
Standard InChI Key: WSECFSPSIZWXKX-SGURQHNMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 583.69 | Molecular Weight (Monoisotopic): 583.2907 | AlogP: 4.30 | #Rotatable Bonds: 7 |
Polar Surface Area: 120.22 | Molecular Species: BASE | HBA: 9 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 9.41 | CX LogP: 2.34 | CX LogD: 0.36 |
Aromatic Rings: 4 | Heavy Atoms: 43 | QED Weighted: 0.34 | Np Likeness Score: -0.68 |
1. Sabnis RW.. (2022) Novel Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors., 13 (10.0): [PMID:36267127] [10.1021/acsmedchemlett.2c00387] |
Source(1):